AGEPHA Pharma FZ LLC
$93.7K 510 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Seapearl East, Inc
Seapearl East, Inc reported $93,858.74 across General Payments, Research, and Ownership to 982 physicians and teaching hospitals across 982 transactions.
- $93.9K Below-median payer
- All-tracks total
- 982 Above-median volume
- Transactions
- 982 Above-median reach
- Recipients
- +$15.7K
- General Payments vs PY2023
Seapearl East, Inc reported $93,858.74 across all CMS Open Payments tracks (General + Research + Ownership) to 982 physicians and teaching hospitals in Program Year 2024 - ranking #1199 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $93,858.74, averaging $95.58 per recipient.
How Seapearl East, Inc's $93.9K all-tracks total breaks down
Seapearl East, Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
17/100
Total payments
F
11/100
Transaction volume
F
17/100
Physician reach
F
17/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer seapearl-east-inc Seapearl East, Inc
$93.9K · #1199/1,925 · 0.0% industry · PY2024
- TOT $93.9K
- RANK #1199
- SHARE 0.0%
- TXN 982
- RCP 982
- CAT 2
- GEN $93.9K
- ΔGEN +$15.7K
- TOP1 3.0%
- PY 2024
Volume peers
Nearest volume peer: AGEPHA Pharma FZ LLC ($93.7K)
Seapearl East, Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Seapearl East, Inc's CMS-reported General Payments increased by $15.7K (+20.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SEAPEARL EAST, INCPY2023: SEAPEARL EAST, INCPY2024: Seapearl East, Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $78,131.42
- PY2024
- $93,858.74
What the Data Shows for Seapearl East, Inc
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Seapearl East, Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
Of the 2 general-payment categories charted below, "Travel and Lodging" is the largest at $49.5K across 207 transactions, 52.8% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Seapearl East, Inc made 2 types of general payments. "Travel and Lodging" is the largest category at $49.5K, 52.8% of General Payments.
How Seapearl East, Inc divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $49.5K | 207 | 52.8% |
| Food and Beverage | $44.3K | 775 | 47.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $9,702.22 (10.3%) of $93,858.74 in this company's General Payments records across 434 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Seapearl East, Inc
The five named recipients with the highest reported General Payments from this company
- 1
Kimberly Tucker
$2,793.05 across 23 reported transactions
- 2
Paul Brown
$2,255.51 across 7 reported transactions
- 3
Jonathan Shearin
$1,842.69 across 15 reported transactions
- 4
Michael Dinizo
$1,408.45 across 5 reported transactions
- 5
Jason Baynes
$1,402.52 across 8 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Seapearl East, Inc ranks #1199 of 1,925 by total payments (bottom 38% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,715 of 1,838 by HHI (bottom 7% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Vertical Pharmaceuticals, LLC : $60.9K total payments, HHI 86
- Sight Sciences, Inc. : $1.0M total payments, HHI 85
- Astellas Pharma US Inc : $10.6M total payments, HHI 85
- Centrix Inc : $17.9K total payments, HHI 84
- Endologix LLC : $725.4K total payments, HHI 84
- Novartis Pharmaceuticals Corporation : $19.7M total payments, HHI 84
- Seapearl East, Inc (this company) : $93.9K total payments, HHI 83
- Spinal Elements, Inc. : $50.6K total payments, HHI 83
- Tris Pharma Inc : $742.6K total payments, HHI 83
- Aquestive Therapeutics, Inc. : $5.5K total payments, HHI 81
- Notal Vision, Inc. : $13.1K total payments, HHI 81
- Atricure, Inc. : $4.9M total payments, HHI 80
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Seapearl East, Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Seapearl East, Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Seapearl East, Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
OnMark, Inc.
$93.7K 63 recipients
Compare payment profiles
Accriva Diagnostics Inc.
$94.1K 0 recipients
Compare payment profiles
Oasis Medical, Inc.
$94.3K 82 recipients
Compare payment profiles
Banner Life Sciences, LLC
$92.8K 2,044 recipients
Compare payment profiles
Mitsubishi Tanabe Pharma Corporation
$92.7K 45 recipients
Compare payment profiles
Put this to use
Seapearl East, Inc ranks #1199 of 1,925 by all-tracks total payments, led by "Travel and Lodging".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Travel and Lodging" spend across every manufacturer, not just Seapearl East, Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.